Journal
CANCERS
Volume 11, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/cancers11101418
Keywords
estrogens; estrogen receptors (ERs); prostate cancer (PC); epithelial mesenchymal transition (EMT); metastasis
Categories
Funding
- Italian Ministry of University and Scientific Research [P.R.I.N. 2015B7M39T_003, P.R.I.N. 2017EKMFTN_002]
- P.O.R-Regione Calabria [Progetto Razionale]
- P.R.I.N. [P.R.I.N. 2010NFEB9L]
- VALERE (Vanvitelli per la Ricerca) Program
- 'Fondazione Umberto Veronesi' [FUV]
Ask authors/readers for more resources
Prostate cancer (PC) remains a widespread malignancy in men. Since the androgen/androgen receptor (AR) axis is associated with the pathogenesis of prostate cancer, suppression of AR-dependent signaling by androgen deprivation therapy (ADT) still represents the primary intervention for this disease. Despite the initial response, prostate cancer frequently develops resistance to ADT and progresses. As such, the disease becomes metastatic and few therapeutic options are available at this stage. Although the majority of studies are focused on the role of AR signaling, compelling evidence has shown that estrogens and their receptors control prostate cancer initiation and progression through a still debated mechanism. Epithelial versus mesenchymal transition (EMT) is involved in metastatic spread as well as drug-resistance of human cancers, and many studies on the role of this process in prostate cancer progression have been reported. We discuss here the findings on the role of estrogen/estrogen receptor (ER) axis in epithelial versus mesenchymal transition of prostate cancer cells. The pending questions concerning this issue are presented, together with the impact of the available data in clinical management of prostate cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available